Should we remind ourselves that the Crispr-Cas9 gene-editing tool is still considered an experimental technology? According to a U.S. study, significant and frequent mutations have ...

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

According to Nova One Advisor, the global CRISPR-based gene editing market size is expected to be worth around 24.37 billion by 2034, increasing from USD 7.06 billion in 2025, representing a healthy ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. In public health emergencies or in resource-constrained settings, laboratory-based ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

The biotechnology industry continues to be at the forefront of scientific innovation, driving breakthroughs in medicine, agriculture, and environmental sustainability. As we look ahead to 2025, a new ...